We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Less-Sensitive COVID-19 Tests Could Still Achieve Optimal Results If Enough People Are Tested

By LabMedica International staff writers
Posted on 27 Jul 2021
Print article
Illustration
Illustration
A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used.

Researchers from Ashoka University (Haryana, India) and the National Centre for Biological Sciences TIFR (Bangalore, India) used computational models to conduct simulations of how COVID-19 spreads among a population, given different combinations of tests and the economic tradeoffs between them. Accounting for the movement of people between different locations, they calculated the total number of infections that would occur by the end of a pandemic under each scenario.

Different states in India use different mixes of two main tests for COVID-19: a very sensitive reverse-transcriptase polymerase-chain-reaction (RT-PCR) test and a less sensitive rapid antigen test. Traditional thinking holds that an all-RT-PCR approach will ultimately lead to fewer overall infections. While RT-PCR tests are more sensitive than rapid antigen tests, they are more expensive and do not provide results immediately. Therefore, the precise mix of tests needed to optimize outcomes while accounting for cost constraints has been unclear.

Their analysis suggests that using only rapid antigen tests could achieve similar outcomes, in terms of total infections, as using only RT-PCR tests - as long as the number of people tested is high enough. This suggests that governments in lower and middle-income countries might be able to achieve optimal outcomes by concentrating on ramping up testing using less sensitive tests which provide immediate results, rather than favoring RT-PCR.

The researchers also note that governments should continue to explore different mixes of tests that will yield the biggest reduction in the number of cases. Given that the costs of testing are falling, this mix could also be recalibrated regularly to monitor what makes the most economic sense.

"Tests are continually improving, and the tradeoffs are in favor of rapid testing, even if it is less sensitive," said Gautam Menon of Ashoka University. "Modeling the effects of using different combinations of tests, keeping in mind their relative costs, can suggest specific policy changes that will have a substantial effect on changing the trajectory of the epidemic."

Related Links:
Ashoka University
National Centre for Biological Sciences


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more